Breast cancer drug may hold key to tackling most deadly type of melanoma

Breast cancer drug may hold key to tackling most deadly type of melanoma

23 July 2019

Barbara Holland tried everything to stop headaches for months before her doctor sent her for an MRI. Her scans showed a tumour in her sinus passages, and four tumours in her brain. In August 2015, she was diagnosed with mucosal melanoma.

Mucosal melanoma, which occurs on the inner surfaces of the body such as the mouth, nose and anogenital region and is not linked to UV exposure, has a very poor prognosis with less than 20% of patients surviving five years after diagnosis.

Now, an Australian-led international team of researchers has discovered that a drug traditionally used to treat a type of breast cancer may hold the key to treating this aggressive and deadly form of melanoma.

The international study, led by researchers from Melanoma Institute Australia, QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has uncovered the diverse genetic drivers for mucosal melanoma as well as identified potential treatments.

Lead study author Professor Richard Scolyer, Co-Medical Director Melanoma Institute Australia, The University of Sydney and Royal Prince Alfred Hospital says the study allowed researchers to not only look for new drug targets, but to also match available targeted drugs to the specific genetic drivers in mucosal melanoma.

“We now understand the genetic drivers of mucosal melanoma, and can match those to potential treatments,” Professor Scolyer said. The study revealed that a currently available class of drug commonly used to treat breast cancer looks promising for treating mucosal melanoma.

“The ramifications of this study are immense and are critical in us reaching our goal of zero deaths from melanoma.”

Published online at Nature Communications, the study detailed the genetic analysis of 67 mucosal melanoma tumours from patients from Australia, China, the United States and Europe. Using both whole-genome sequencing and whole-exome sequencing, the authors identified diverse drivers that suggested that mucosal melanoma has potential therapeutic targets.

The majority of mucosal melanomas sequenced in the study showed potential susceptibility to currently available classes of drug. One in particular, CDK4/6 inhibitors, are a class of drug used to treat HR-positive, HER2-negative breast cancer.

“While advancements in treatment have drastically improved survival outcomes for cutaneous (or skin) melanoma patients, those treatments do not work as well for mucosal melanoma patients,” Professor Scolyer added.

“But now we can build our treatment arsenal for this group of patients – starting with CDK4/6 inhibitors used to treat a subtype of breast cancer.”

The study also found possible reasons why mucosal melanoma is less responsive to immunotherapy which has had such success in saving the lives of UV-related melanoma patients. It revealed that a mutation in some mucosal melanomas locks immune cells out of the tumour, rendering immunotherapy treatment ineffective.

“I’m one of the lucky ones,” said Barbara.

The tumour in her sinuses was removed with surgery, and after three years of immunotherapy, one of her brain tumours is no longer measurable and the others are stable.

“This news is so exciting for other mucosal patients and their families. Hopefully in the near future, they will be able to have the same positivity that I have.”

While rare in Western populations like in Australia, where it makes up less than 2% of all melanoma cases, mucosal melanoma makes up a third of all melanoma cases worldwide.

A previous study also coming from the Australian Melanoma Genome Project found that mucosal melanoma is not linked to UV radiation, as is the case with cutaneous (or skin) melanoma.

There are no known risk factors for mucosal melanoma, making prevention strategies difficult. It is also usually diagnosed at a later stage of disease due to the challenges of monitoring sites where it is found – the internal surfaces of the body.

“The next exciting step is for Melanoma Institute Australia to develop a clinical trial to test classes of drugs and their effectiveness for treating mucosal melanoma,” said study author Professor Georgina Long, Co-Medical Director Melanoma Institute Australia The University of Sydney and Royal North Shore Hospital

“This is the new frontier in melanoma treatment, with very real benefits for patients internationally, and we are proud to be leading the world in saving lives.”

Barbara is no longer on treatment and comes to MIA for three monthly scans.

“It’s amazing to know that there could soon be new treatments for this horrible disease. I think the best part about this discovery is that it gives hope,” said Barbara.

Next Steps for National Screening Program for Melanoma
23 Mar 2020

Next Steps for National Screening Program for Melanoma

On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.

Melanoma March Update
13 Mar 2020

Melanoma March Update

Melanoma March events have been cancelled. A Virtual March will be held on Sunday 29th March. Read this statement from MIA CEO Matthew Browne.   

Saving lives this summer: 'Game On Mole!'
11 Mar 2020

Saving lives this summer: 'Game On Mole!'

Thank you to the thousands of Aussies who bought ‘Game On Mole‘ t-shirts, took selfies, shared t-shirt pics on social media and started lifesaving conversations around sun safety and skin health.

PBS boost for melanoma patients
01 Mar 2020

PBS boost for melanoma patients

Melanoma patients now have greater access to subsidised immunotherapy thanks to additional treatments today being listed on the PBS.

An open letter to all young Australians
25 Feb 2020

An open letter to all young Australians

Brisbane couple Leon and Tamra Betts were, like thousands of others around Australia, on the couch watching MAFS when newlywed Natasha ran through her weekly beauty routine. When they heard the 26-year-old mention solarium use, they were shocked, and then saddened, prompting this open letter to all young Australians.

MIA leads world-class skin tumour pathology conference
14 Feb 2020

MIA leads world-class skin tumour pathology conference

Professor Richard Scolyer, Co-Medical Director of Melanoma Institute Australia, will welcome international attendees this weekend to a sold-out, two-day course on ‘Pigmented Lesions and Other Hot Topics in Dermatopathology’.

MAFS, it is time for a reality check on solariums.
07 Feb 2020

MAFS, it is time for a reality check on solariums.

It is time for a reality check on solariums.
They have no place in anyone’s beauty routine.

Community Fundraising January Wrap-Up
07 Feb 2020

Community Fundraising January Wrap-Up

Throughout January our community created, hosted and participated in some amazing events, each of them helping us on our quest to reach zero deaths from melanoma.

Kyly Clarke urges Aussies to step up to save lives from melanoma
03 Feb 2020

Kyly Clarke urges Aussies to step up to save lives from melanoma

Australian television presenter, interior designer and mother Kyly Clarke has been announced as the new Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign Melanoma March.

Improving support for our patients across Australia.
03 Feb 2020

Improving support for our patients across Australia.

Melanoma Institute Australia has recently partnered with three other organisations to boost support for melanoma patients and their carers across Australia.   

Boost to melanoma support in WA
31 Jan 2020

Boost to melanoma support in WA

Melanoma patients and their families across Western Australia will benefit from strengthened and expanded services with the merging of melanomaWA and Melanoma Institute Australia.

New Test to Predict Primary Melanoma Progression
21 Jan 2020

New Test to Predict Primary Melanoma Progression

Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.

Community Fundraising December Wrap-Up
14 Jan 2020

Community Fundraising December Wrap-Up

We are extremely grateful for our community fundraisers, who, even in this difficult time, have given up their time and effort to fundraise so we can continue to work towards our goal of zero deaths from melanoma.

Two melanoma treatments approved for PBS listing
24 Dec 2019

Two melanoma treatments approved for PBS listing

Melanoma patients are set to benefit from subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients.    

Immunotherapy: the decade's biggest health advance
23 Dec 2019

Immunotherapy: the decade's biggest health advance

An informative article on how immunotherapy is revolutionising cancer treatment, written by Jill Margo and featured in the Australian Financial Review.  

 

Boost to Melanoma Services in the Riverina
12 Dec 2019

Boost to Melanoma Services in the Riverina

Melanoma patients and their families in the Riverina will benefit from strengthened and sustained melanoma services with the merger of the Amie St Clair Melanoma Trust and Melanoma Institute Australia.

Winner of the SunSafe Student Ambassador Program announced
11 Dec 2019

Winner of the SunSafe Student Ambassador Program announced

Belmont High School at Lake Macquarie has been announced winner of the 2019 SunSafe Student Ambassador Program video competition.

Community Fundraising November Wrap-Up
04 Dec 2019

Community Fundraising November Wrap-Up

It’s time again to say thank you to our amazing community fundraisers!

MIA & MPA Patient Information Evening videos now available
03 Dec 2019

MIA & MPA Patient Information Evening videos now available

Videos of the sessions at the recent Patient Information Evening co-hosted by Melanoma Institute Australia (MIA) and Melanoma Patients Australia (MPA) are now available for viewing.

MIA shines in poster session
22 Nov 2019

MIA shines in poster session

MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.